A randomized controlled study of trimethoprim-sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients

Journal of Digestive Diseases

Volumn 15, Issue 5, 2014, Pages 260-267

  Lontos, Steve ^a   Shelton, Edward ^a   Angus, Peter W ^a   Vaughan, Rhys ^a   Roberts, Stuart K ^a   Gordon, Adam ^a   Gow, Paul J ^a  

^a ALFRED HOSPITAL   (Australia)

Author keywords

Infection; Liver cirrhosis; Norfloxacin; Prevention; Trimethoprim sulfamethoxazole combination

Indexed keywords

ALBUMIN; AMPICILLIN; BILIRUBIN; CEFTRIAXONE; COTRIMOXAZOLE; NORFLOXACIN; ANTIINFECTIVE AGENT;

ADULT; ALCOHOL CONSUMPTION; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; ASCITES FLUID; BACTEREMIA; BACTERIAL PERITONITIS; BACTERIUM CULTURE; BILIRUBIN BLOOD LEVEL; CAUSE OF DEATH; CELLULITIS; CHILD PUGH SCORE; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HUMAN; INCIDENCE; INFECTION PREVENTION; KIDNEY DISEASE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PARANOIA; PATIENT COMPLIANCE; PERITONITIS; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SKIN DISEASE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; BACTERIAL INFECTIONS; COMPARATIVE STUDY; COMPLICATION; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTEREMIA; BACTERIAL INFECTIONS; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NORFLOXACIN; PERITONITIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84898879377     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12132     Document Type: Article

References (23)

1. Fernández J, Navasa M, Gómez J etal. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35: 140-148.
2. Saab S, Hernandez JC, Chi AC, Tong MJ. Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: a meta-analysis. Am J Gastroenterol 2009; 104: 993-1001.
3. Titó L, Rimola A, Ginès P, Llach J, Arroyo V, Rodés J. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988; 8: 27-31.
4. Llach J, Rimola A, Navasa M etal. Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration. Hepatology 1992; 16: 724-727.
5. Runyon BA. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology 1986; 91: 1343-1346.
6. Andreu M, Sola R, Sitges-Serra A etal. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 1993; 104: 1133-1138.
7. Fernández J, Acevedo J, Castro M etal. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012; 55: 1551-1561.
8. Singh N, Gayowski T, Yu VL, Wagener MM. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med 1995; 122: 595-598.
9. Lontos S, Gow PJ, Vaughan RB, Angus PW. Norfloxacin and trimethoprim-sulfamethoxazole therapy have similar efficacy in prevention of spontaneous bacterial peritonitis. J Gastroenterol Hepatol 2008; 23: 252-255.
10. Runyon BA; AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology 2013; 57: 1651-1653.
11. Soriano G, Guarner C, Teixidó M etal. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991; 100: 477-481.
12. Grangé JD, Roulot D, Pelletier G etal. Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. J Hepatol 1998; 29: 430-436.
13. Novella M, Solà R, Soriano G etal. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology 1997; 25: 532-536.
14. Alvarez RF, Mattos AA, Corrêa EB, Cotrim HP, Nascimento TV. Trimethoprim-sulfamethoxazole versus norfloxacin in the prophylaxis of spontaneous bacterial peritonitis in cirrhosis. Arg Gastroenterol 2005; 42: 256-262.
15. Fernández J, Navasa M, Planas R etal. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133: 818-824.
16. Ginés P, Rimola A, Planas R etal. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990; 12: 716-724.
17. Bauer TM, Follo A, Navasa M etal. Daily norfloxacin is more effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence. Dig Dis Sci 2002; 47: 1356-1361.
18. Kundu AK. Norfloxacin-induced hallucination - an unusual CNS toxicity of 4-fluoroquinolones. J Assoc Physicians India 2000; 48: 944.
19. Delanaye P, Mariat C, Cavalier E, Maillard N, Krzesinski JM, White CA. Trimethoprim, creatinine and creatinine-based equations. Nephron Clin Pract 2011; 119: c187-194.
20. Merli M, Lucidi C, Giannelli V etal. Cirrhotic patients are at risk for health care-associated bacterial infections. Clin Gastroenterol Hepatol 2010; 8: 979-985.
21. Findlay JY, Fix OK, Paugam-Burtz C etal. Critical care of the end-stage liver disease patient awaiting liver transplantation. Liver Transpl 2011; 17: 496-510.
22. Australian Government, Department of Health. Trimethoprim + sulfamethoxazole. Cited: 6 Mar 2014. Available from URL: http://www.pbs.gov.au/medicine/item/2951H-3103H-3390K-3391L
23. Australian Government, Department of Health. Norfloxacin. Cited: 6 Mar 2014. Available from URL: http://www.pbs.gov.au/medicine/item/3010K